Welcome to our dedicated page for EMMAUS LIFE SCIENCES news (Ticker: EMMA), a resource for investors and traders seeking the latest updates and insights on EMMAUS LIFE SCIENCES stock.
Emmaus Life Sciences develops, markets, and sells biopharmaceutical therapies focused on sickle cell disease, led by Endari® (prescription-grade L-glutamine oral powder). News about EMMA commonly covers financial results, Endari commercialization, FDA labeling activity, competition from generic L-glutamine, and sales trends across the U.S. and international markets.
Company updates also address market access and distribution strategy for Endari, including activity in the Middle East and North Africa region and Saudi Arabia. Emmaus reports operating expenses, liquidity, and other financial items alongside product safety and indication information for Endari, which is approved to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Emmaus Life Sciences (OTCQB: EMMA) announced that its sickle cell disease treatment, Endari® (L-glutamine oral powder), has been granted market exclusivity in the Kingdom of Saudi Arabia (KSA) by the National Uniform Procurement Agency (NUPCO). The initial exclusivity period is one year, with potential extension to three years upon marketing registration approval.
The exclusivity applies across all KSA government institutions, including Ministry of Health hospitals, Military Hospitals, National Guard, Security Forces, and King Faisal Specialty Hospitals and Research Centers. This represents a significant opportunity in the KSA's healthcare system for treating sickle cell disease patients.
Emmaus Life Sciences (OTCQB: EMMA) reported Q3 2024 financial results with net revenues of $5.5 million, up 9% from Q3 2023, and net income of $1.8 million, a 2,626% increase. The company resumed inventory production in August, leading to improved quarterly performance. However, year-to-date net revenues decreased 41% due to earlier inventory shortages. Operating expenses decreased to $4.3 million in Q3 2024 from $4.8 million in Q3 2023. The launch of a competing generic L-Glutamine Oral Powder in July may impact future Endari sales. Cash position stood at $1.3 million as of September 30, 2024.
Emmaus Life Sciences (OTC: EMMA) reported financial results for Q1 and Q2 2024. Key points:
- Net revenues for H1 2024 were $7.9 million, down 55% from $17.5 million in H1 2023 due to inventory shortages.
- Operating loss of $2.2 million in H1 2024, compared to $2.2 million income in H1 2023.
- Net loss of $6.5 million ($0.10 per share) in H1 2024, versus $5.0 million loss in H1 2023.
- Cash and equivalents of $1.5 million as of June 30, 2024.
The company doesn't expect 2024 full-year revenues to reach 2023 levels. It's working with alternative manufacturers to avoid future shortages and assessing the impact of a new generic competitor.
Emmaus Life Sciences (OTCMarkets: EMMA), a leader in sickle cell disease treatment, has appointed Willis C. Lee as its new Chief Executive Officer. Lee, previously serving as Co-President and Chief Operating Officer, will retain his position as Chairman of the Board. The company is focusing on improving operational efficiency and preparing for challenges posed by the launch of generic L-glutamine.
Lee emphasized plans to grow market presence in the Middle East and invest in research to expand pipelines and increase company value. He committed to working closely with the Board, restructured teams, and stakeholders to justify their trust in the company's future.
Emmaus Life Sciences (OTCPK: EMMA), a leader in sickle cell disease treatment, announced receiving a 'No Action Indicated' (NAI) classification following a routine FDA inspection of its Postmarketing Adverse Drug Experience (PADE) compliance program. This signifies no objectionable conditions or practices were found in the six years since Endari® has been marketed. This classification places Emmaus within the top 16% of companies inspected in 2019, highlighting their commitment to high-quality and safe medications. The inspection, conducted by two FDA Consumer Safety Officers over two and a half days, underscores Emmaus' dedication to regulatory compliance and patient safety.
Emmaus Life Sciences (OTCPK: EMMA), a biopharmaceutical company specializing in sickle cell disease treatment, released its 2023 financial results. The company reported a 61% increase in annual net revenues, reaching $29.6 million, driven by higher sales in the MENA region and the U.S. Income from operations rose to $3.5 million from a loss of $6.6 million in 2022. However, the net loss was $3.7 million, a notable improvement from the $10.6 million loss in 2022. The company faced a slowdown in Endari sales in Q4 2023 due to inventory shortages, impacting sales in Q1 and Q2 2024. Emmaus has since addressed the shortage and is working with alternative manufacturers. Operating expenses increased to $24.7 million from $22.4 million in 2022, primarily due to higher administrative and selling expenses. The company held $2.5 million in cash and cash equivalents as of December 31, 2023.
Summary not available.
Summary not available.
Summary not available.
Summary not available.